Future cardiology · 2026
Combination pitavastatin-ezetimibe therapy for hypercholesterolemia and mixed dyslipidemia: a systematic review and meta-analysis.
Систематический обзорСтатьяМетаанализНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Abbas Muhammad Sharjeel, Batool Asia, Hussain Muhammad, Hassan Muhammad, Sohaib Asharib, Ahmed Taha, Athar Maryam, Khan Saifullah, Kanwal Warisha, Ali Akbar Makhzan, Hannan Abdul
Аннотация
BACKGROUND: Dyslipidemia is a prevalent and major contributor to atherosclerotic cardiovascular disease; however, many patients do not achieve the recommended low-density lipoprotein cholesterol goals with statin monotherapy. Thus, the efficacy of complementary therapeutic options must be investigated.
OBJECTIVE: To evaluate the lipid-lowering efficacy and safety of pitavastatin combined with ezetimibe versus pitavastatin monotherapy in adults with hypercholesterolemia or mixed dyslipidemia.
METHODS: A systematic search of PubMed, Embase, Cochrane Library, and Scopus (November 2025) identified randomized controlled trials that compared pitavastatin 2 mg or 4 mg plus ezetimibe 10 mg with pitavastatin 2 mg alone. The protocol for this systematic review and meta-analysis was prospectively registered in PROSPERO. A random-effects meta-analysis was used to pool lipid and safety outcomes. The risk of bias was assessed using RoB 2, and the certainty of evidence was graded using the GRADE tool.
RESULTS: Non-high-density lipoprotein cholesterol, total cholesterol, and Apolipoprotein B. Changes in high-density lipoprotein cholesterol and triglyceride levels were modest but more pronounced at week 12.
CONCLUSION: Combination therapy offers an apparent enhancement in lipid lowering and may serve as an effective supplementary option for patients who require more intensive low-density lipoprotein cholesterol management. However, the limited evidence warrants further research.
PROTOCOL REGISTRATION: www.crd.york.ac.uk/prospero identifier is CRD420251233057.
OBJECTIVE: To evaluate the lipid-lowering efficacy and safety of pitavastatin combined with ezetimibe versus pitavastatin monotherapy in adults with hypercholesterolemia or mixed dyslipidemia.
METHODS: A systematic search of PubMed, Embase, Cochrane Library, and Scopus (November 2025) identified randomized controlled trials that compared pitavastatin 2 mg or 4 mg plus ezetimibe 10 mg with pitavastatin 2 mg alone. The protocol for this systematic review and meta-analysis was prospectively registered in PROSPERO. A random-effects meta-analysis was used to pool lipid and safety outcomes. The risk of bias was assessed using RoB 2, and the certainty of evidence was graded using the GRADE tool.
RESULTS: Non-high-density lipoprotein cholesterol, total cholesterol, and Apolipoprotein B. Changes in high-density lipoprotein cholesterol and triglyceride levels were modest but more pronounced at week 12.
CONCLUSION: Combination therapy offers an apparent enhancement in lipid lowering and may serve as an effective supplementary option for patients who require more intensive low-density lipoprotein cholesterol management. However, the limited evidence warrants further research.
PROTOCOL REGISTRATION: www.crd.york.ac.uk/prospero identifier is CRD420251233057.